Track market-moving stories before they get noisy

Wave Life Sciences (WVE - Free Report) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to a loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.

This quarterly report represents an earnings surprise of +61.31%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.28 per share when it actually produced a loss of $0.3, delivering a surprise of -7.14%.

Over the last four quarters, the company has surpassed consensus EPS estimates just once.

Wave Life Sciences, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $38.25 million for the quarter ended March 2026, surpassing the Zacks Consensus Estimate by 256.61%. This compares to year-ago revenues of $9.18 million. The company has topped consensus revenue estimates two times over the last four quarters.

The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call.

Wave Life Sciences shares have lost about 59.2% since the beginning of the year versus the S&P 500's gain of 4.8%.

What's Next for Wave Life Sciences?While Wave Life Sciences has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock?

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately.

Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions.

Ahead of this earnings release, the estimate revisions trend for Wave Life Sciences was mixed. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #3 (Hold) for the stock. So, the shares are expected to perform in line with the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.

It will be interesting to see how estimates for the coming quarters and the current fiscal year change in the days ahead. The current consensus EPS estimate is -$0.37 on $8.45 million in revenues for the coming quarter and -$1.39 on $37.78 million in revenues for the current fiscal year.

Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Medical - Biomedical and Genetics is currently in the bottom 41% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1.

One other stock from the same industry, Kymera Therapeutics, Inc. (KYMR - Free Report) , is yet to report results for the quarter ended March 2026. The results are expected to be released on April 30.

This company is expected to post quarterly loss of $0.89 per share in its upcoming report, which represents a year-over-year change of -8.5%. The consensus EPS estimate for the quarter has been revised 1.4% lower over the last 30 days to the current level.

Kymera Therapeutics, Inc.'s revenues are expected to be $11.02 million, down 50.1% from the year-ago quarter.

Data reinforce WVE-006's potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing

The sponsorship helps expand proven strategies to consistently detect a genetic, irreversible, and progressive condition in patients with liver and/or lung disease.

, /PRNewswire/ -- AlphaDetect, the nonprofit organization powered and funded by the Alpha-1 Foundation (A1F), today announced Wave Life Sciences as an inaugural industry sponsor. The support further strengthens efforts to accelerate routine targeted detection of Alpha-1 Antitrypsin Deficiency (Alpha-1) in people impacted by liver and/or lung disease, consistent with clinical practice guidelines.

Wave Life Science AlphaDetect is dedicated to identifying everyone at risk for this progressive, irreversible genetic condition by elevating awareness and removing barriers to detection. The organization will provide free genetic testing for Alpha-1 in their proprietary laboratory, at no cost to insurance or patients. In addition, they provide support from a committed engagement team for healthcare providers. These efforts will increase the availability of Alpha-1 detection tools and support at the practice level while also partnering with healthcare providers to strategically advance protocols and technologies across healthcare systems.

"We know from conversations with the Alpha-1 community that AATD (Alpha-1 Antitrypsin Deficiency) is highly underdiagnosed and often misdiagnosed. We're proud to support AlphaDetect as an inaugural sponsor and especially excited about this centralized lab for Alpha-1 testing and detection, supported by a team dedicated to the Alpha-1 community," said Christopher Wright, MD, PhD, Chief Medical Officer at Wave Life Sciences. "In addition to genetic testing, AlphaDetect is part of a broader effort to connect people living with Alpha-1 to care, resources, and ongoing research that may potentially have a significant impact on their quality of life and the progression of their disease."

"Alpha-1 is a progressive, genetic lung and liver condition where delays in detection may have real, irreversible consequences," said Julie Murray, CEO of AlphaDetect. "The ability to scale proven approaches to identifying at-risk patients, quickly and systematically, can inform timely decisions for those impacted. The support and commitment from Wave Life Sciences are important and appreciated as we continue to advance Alpha-1 detection."

Alpha-1 remains significantly underdiagnosed, with more than 90% of affected individuals estimated to be unidentified. It is also the leading known genetic risk factor for COPD and is associated with liver disease in both children and adults. Importantly, detection also provides a point of entry into the Alpha-1 community, opening the door to the comprehensive information, support, and resources needed for the journey ahead.

"This support builds on Wave Life Science's focus on novel approaches to support the Alpha-1 community and represents an important step forward in how we advance detection," said Scott Santarella, CEO of the Alpha-1 Foundation. "By expanding these efforts through AlphaDetect, we can identify more individuals earlier and deliver on A1F's mission of improving their lives."

The latest clinical guidelines recommend testing for Alpha-1 in all individuals with COPD, treatment-resistant asthma, or unexplained liver disease. Yet real-world results fall far short of this. AlphaDetect is committed to closing the gap. Wave Life Science's sponsorship and commitment will help AlphaDetect scale efforts to enhance provider education, broaden detection strategies, and work across the Alpha-1 community to identify individuals with Alpha-1.

About AlphaDetect 

AlphaDetect, founded in 2025, accelerates detection to uncover everyone genetically at risk for Alpha-1. Located in Durham, NC, AlphaDetect will operate as a limited liability company and a non-profit subsidiary of Alpha-1 Foundation, holding tax-exempt status under Section 501(c)3 of the Internal Revenue Code. 

For more information, visit https://alpha1.org/alphadetect/

Contact: Cindy Machles

917-453-9760

Email: [email protected]

About Wave Life Sciences

Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave's RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave's pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington's disease, as well as several preclinical programs utilizing the company's versatile RNA medicines platform. Driven by the calling to "Reimagine Possible," Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave's science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

For more information, visit www.wavelifesciences.com

Contact: Katie Sullivan

Senior Director, Corporate Communications

617-949-2936

[email protected]

About the Alpha-1 Foundation

The Alpha-1 Foundation, founded in 1995, is committed to finding a cure for Alpha-1 Antitrypsin Deficiency (Alpha-1) and to improving the lives of people affected by the condition worldwide. A1F has invested over $100 million to support Alpha-1 research and programs at 130 institutions in North America, Europe, the Middle East and Australia.

For more information, visit alpha1.org

Contact: Jeanne Kushner

Senior Director of Communications & Policy

877-228-7321

[email protected]

SOURCE Alpha-1 Foundation

SAN DIEGO, May 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Wave Life Sciences Ltd. (NASDAQ: WVE) or certain of its executive officers violated federal securities laws. The investigation focuses on investors’ losses and whether they may be recovered under federal securities laws.

What if I purchased Wave Life Sciences securities?
If you purchased Wave Life Sciences securities and suffered losses on your investment, join our investigation now: Click Here to Join the Investigation.

Or for more information, contact Jim Baker at [email protected] or (619) 814-4471.

There is no cost or obligation to you.

Background of the Investigation
On March 26, 2026, Wave Life Sciences announced positive interim Phase 1 data from INLIGHT, its clinical trial evaluating WVE-007, an investigational INHBE GalNAc-siRNA for people living with overweight or obesity.

Wave reported that, at six-month follow-up, a single 240 mg dose of WVE-007 produced placebo-adjusted reductions in visceral fat of 14.3%, total fat of 5.3%, waist circumference of 3.3%, and body weight of 0.9%, while lean mass increased 2.4%. The Company also reported that, in the 400 mg cohort, three-month data showed placebo-adjusted reductions in visceral fat of 5.0% and total fat of 0.7%, with lean mass preservation.

Following this news, Wave’s stock declined sharply, damaging investors.

In light of these disclosures, Johnson Fistel is investigating whether Wave Life Sciences complied with state and federal laws, including the federal securities laws. If you suffered losses, or are a long-term holder of Wave Life Sciences stock, contact Johnson Fistel.

About Johnson Fistel, PLLP | Top Law Firm – Securities Fraud & Investor Rights
Johnson Fistel, PLLP is a nationally recognized shareholder rights law firm with offices in California, New York, Georgia, Idaho, and Colorado. The firm represents individual and institutional investors in shareholder class actions and derivative lawsuits. Johnson Fistel has been recognized as one of the Top 10 Plaintiff Law Firms by ISS Securities Class Action Services. In 2024, the firm recovered approximately $90,725,000 for investors.

Attorney advertising.
Past results do not guarantee future outcomes.
Services may be performed by attorneys in any of our offices.
Johnson Fistel, PLLP has paid for the dissemination of this promotional communication, and Frank J. Johnson is the attorney responsible for its content.

Contact
Johnson Fistel, PLLP
501 W. Broadway, Suite 800
San Diego, CA 92101
James Baker, Investor Relations – or – Frank J. Johnson, Esq.
(619) 814-4471 | [email protected] | [email protected]

June 01, 2026 08:30 ET  | Source: Wave Life Sciences USA, Inc.

CAMBRIDGE, Mass., June 01, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that members of Wave’s management team are scheduled to participate in two upcoming investor conferences in June.

2026 Jefferies Global Healthcare Conference
Date: Wednesday, June 3, 2026
Details: Paul Bolno, MD, MBA, President and CEO, will participate in an analyst-led fireside chat at 10:30 a.m. ET

Goldman Sachs 47th Annual Global Healthcare Conference
Date: Monday, June 8, 2026
Details: Dr. Bolno will participate in an analyst-led fireside chat at 8:00 a.m. ET

Live webcasts of the presentations can be accessed by visiting “Investor Events” on the Investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Replays of these presentations will be archived and available on the site for a limited time following the event.

About Wave Life Sciences
Wave Life Sciences (Nasdaq: WVE) is a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health. Wave’s RNA medicines platform, PRISM®, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and common disorders. Its toolkit of RNA-targeting modalities, including RNAi (SpiNA) and RNA editing (AIMers), provides Wave with unmatched capabilities for designing and sustainably delivering candidates that optimally address disease biology. Wave’s pipeline is focused on its obesity (WVE-007), alpha-1 antitrypsin deficiency (WVE-006) and PNPLA3 I148M liver disease (WVE-008) programs, and also includes clinical programs in Duchenne muscular dystrophy and Huntington’s disease, as well as several preclinical programs utilizing the company’s versatile RNA medicines platform. Driven by the calling to “Reimagine Possible,” Wave is leading the charge toward a world in which human potential is no longer hindered by the burden of disease. Wave is headquartered in Cambridge, MA. For more information on Wave’s science, pipeline and people, please visit www.wavelifesciences.com and follow Wave on X and LinkedIn.

Contact:
Kate Rausch
VP, Corporate Affairs and Investor Relations
+1 617-949-4827

Investors:
James Salierno
Director, Investor Relations
+1 617-949-4043
[email protected]

Media:
Katie Sullivan
Senior Director, Corporate Communications
+1 617-949-2936
[email protected]

WW International (NASDAQ:WW), the global weight management company formerly known as Weight Watchers, released its fourth quarter and full-year 2025 financial results, showing stronger-than-expected earnings despite a year-over-year decline in total revenue. The company's shares surged more than 12% following the report, trading just shy of $24 on Monday morning.

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight health, today announced that eligible Weight Watchers Med+ members will have access to subscription pricing for Wegovy® that significantly reduces out-of-pocket costs and is a result of expanded collaboration between Weight Watchers and Novo Nordisk.

The new subscription offer gives Weight Watchers Med+ members access to the lowest available self-pay price in the market for doses of Wegovy not otherwise available through limited-time offers, saving cash-pay members up to $1,200 per year. The announcement coincides with Novo Nordisk’s launch of the industry’s first-of-its-kind medication subscription pricing model for Wegovy and reinforces Weight Watchers’ role as a NovoCare® Recognized Care Provider and leader in integrated, evidence-based GLP-1 care.

“Novo Nordisk and Weight Watchers are each committed to helping those living with obesity take control of their health–and we are strengthening our collaboration to support that shared mission,” said Ed Cinca, Senior Vice President Marketing and Patient Solutions at Novo Nordisk. “We are making our subscription prices available to Med+ members to help them get and stay on treatment. This subscription option adds to ongoing efforts to meet people where they are, bringing transparency and predictability to those seeking treatment for obesity management.”

Through the new offer, eligible Med+ members with a valid prescription can pre-pay for three, six, or 12 months of Wegovy at a discounted monthly rate, including Wegovy pens across all doses and Wegovy pills at 9 mg and 25 mg doses. Depending on the commitment length, members can save up to $100 per month on pens and up to $50 per month on pills, versus the standard monthly self-pay price. Even without a multi-month commitment, members can take advantage of existing limited-time pricing offers, including starting doses of the Wegovy pill for only $149 per month. These offers give Med+ members best in market pricing for self-pay Wegovy.

“GLP-1s have helped millions across the world take control of their health -- but many more can't access these medications due to high costs.” said Scott Honken, Chief Commercial Officer of Weight Watchers. “That's why Weight Watchers is proud to introduce an expanded collaboration with Novo Nordisk, which gives our eligible Med+ members a more affordable and predictable path to access FDA-approved Wegovy. These reduced costs, combined with our unique lifestyle support system that drives 29% greater weight loss than the drugs alone, will continue to help Weight Watchers deliver the best GLP-1 results on the market.”

The expanded collaboration builds on Weight Watchers’ long-standing relationship with Novo Nordisk and reflects a shared commitment from both Weight Watchers and Novo Nordisk to improve access to FDA-approved weight health treatment.

Weight Watchers’ Med+ platform offers access to board-certified physicians, FDA-approved prescriptions, and lifestyle support to drive better outcomes and create lasting habits that can sustain results over time. Combined with the GLP-1 Success program, the Weight Watchers’ program helps members stay consistent with the tools they need for success throughout their GLP-1 journey.

The new medication commitment pricing offer comes as Weight Watchers’ clinical business grows rapidly, underscoring rising demand for its integrated GLP-1 model as more consumers seek a comprehensive approach to weight health.

As GLP-1 medications continue to reshape obesity care, Weight Watchers remains focused on what drives lasting results: pairing FDA-approved treatment with structured nutritional, behavioral, and lifestyle support. This expanded collaboration with Novo Nordisk marks another step in making that integrated model more affordable, accessible, and sustainable for the people who need it.

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]

New, Independent Directors Bring Deep Consumer, Digital and Turnaround Expertise to Support Strategic Transformation April 07, 2026 07:30 ET  | Source: WW International Inc.

NEW YORK, April 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced that it has appointed accomplished executives, Lisa Gavales and Sue Gove, as independent members of the Company’s Board of Directors, effective April 7, 2026. Ms. Gavales and Ms. Gove will serve as directors until the Company’s 2026 annual meeting of shareholders and are expected to stand for election at the annual meeting. Following these appointments, the Board consists of six directors, all of whom are independent.

Lisa Gavales and Sue Gove are highly regarded consumer brand leaders with distinct expertise that will enhance the Board as Weight Watchers advances its next phase of growth. Ms. Gavales is a consumer and retail executive with a proven track record of building digitally-enabled, multi-channel businesses and strengthening brand engagement at scale. Among her experience, she has served as Chair of the Office of the CEO at Destination Maternity, Interim CEO of Bluestem Group, and previously as Chief Marketing Officer at Express. Ms. Gove has a proven track record of commercial leadership and strong financial acumen across consumer-facing organizations, and also brings extensive public company board experience. Most recently, she was president and CEO and a member of the board of directors of Bed Bath & Beyond after serving as Interim CEO, and brings experience as a CEO, COO and CFO.

Gene Davis, Chairman of the Weight Watchers Board, said, “The Board is committed to overseeing the Company’s transformation into the premier global destination for weight health and to delivering long-term value to shareholders. We are delighted to welcome Lisa and Sue to the Weight Watchers Board and look forward to benefiting from their experience and insights as we work to create long-term value for shareholders.”

Nikolaj Sjoqvist, Chairman of Weight Watchers Nominating and Corporate Governance Committee, said, “The appointments of Lisa and Sue reflect an ongoing process over several months to identify high-caliber directors with the right skills as we support management and position Weight Watchers for sustainable growth. Lisa’s expertise in e-commerce, brand building and customer engagement will contribute to driving continued growth and member acquisition, while Sue’s experience will ensure thoughtful resource prioritization.”

Ms. Gavales said, “I have long admired the Weight Watchers brand and its impact, and I’m pleased to join the Board at an important stage in the Company’s evolution. With a strong foundation and significant opportunity to expand its digital health offerings, I look forward to contributing my experience to advance Weight Watchers' strategic objectives and create value."

Ms. Gove said, “Weight Watchers is an iconic brand and organization that has initiated meaningful transformation over the past year. I look forward to working with my fellow directors and the management team to build on this important strategic direction, provide further financial oversight and support execution.”

About Lisa Gavales
Lisa Gavales is a proven consumer and retail executive with more than 30 years of experience. Most recently, she was Chair of the Office of the CEO at Destination Maternity Corp, the largest maternity apparel retailer in the U.S. She previously served as Interim CEO of Bluestem Group and as President, CEO and Chairman of the Board of Things Remembered. Earlier in her career, she held senior leadership roles at Talbots and Express, including Chief Marketing Officer of Express. Ms. Gavales began her career at Bloomingdale’s, where she spent more than a decade in senior roles across merchandising, marketing, strategic planning and digital commerce.

Ms. Gavales holds an MBA and a B.S. in Marketing from the University of Bridgeport.

About Sue Gove
Sue Gove is an experienced executive and board leader with deep expertise in operational transformation, financial leadership and strategic execution across consumer-facing businesses. Most recently, she was president and CEO and a member of the board of directors of Bed Bath & Beyond. She previously held CEO roles at Vitamin World and Golfsmith International, where she also served as Chief Operating Officer and Chief Financial Officer. Prior to these roles, Ms. Gove began her career at Zale Corporation, America’s largest specialty jewelry retailer, where she held senior leadership positions, including Chief Financial Officer and Chief Operating Officer. In addition, Ms. Gove currently serves on the board of directors of LKQ Corporation.

Ms. Gove holds a B.B.A in Accounting from the University of Texas McCombs School of Business.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the Company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “targets,” “projects,” “contemplates,” “believes,” “estimates,” “forecasts,” “guidance,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. These statements are neither promises nor guarantees, and involve known and unknown risks, uncertainties and other important factors that may cause the Company’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the important factors discussed under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, as well as any subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, or other filings the Company makes with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made in this Form 8-K. Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]

The addition of Foundayo® (orforglipron) gives Weight Watchers Med+ members a new FDA-approved oral GLP-1 option for weight loss April 09, 2026 09:00 ET  | Source: WW International Inc.

NEW YORK, April 09, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers”), the global leader in science-backed weight management, announced that it is now offering access to Eli Lilly and Company’s newly FDA-approved oral GLP-1, Foundayo® (orforglipron) through its Med+ offering and affiliated medical groups. The addition gives members a new once-daily, injection-free option for adults with obesity or overweight with weight-related medical problems and further expands the company’s growing portfolio of FDA-approved oral GLP-1 treatments, all within a clinically supported program designed to help them succeed.

Through Weight Watchers Med+, clinically eligible members will be able to access this newly approved medication alongside care from board-certified clinicians, insurance support, and additional tools designed to support the treatment journey. All Med+ members also receive direct access to the Weight Watchers GLP-1 Success program to support them before, during, and after medication use.

For members choosing self-pay, pricing will start at $149 per month for the lowest dose, with pricing varying by dose.

“As the weight health landscape evolves, it’s important that people have access to a broad range of FDA-approved treatment options that reflect different needs, preferences, and routines,” said Scott Honken, Chief Commercial Officer at Weight Watchers. “With this new offering, Weight Watchers is expanding access to a new FDA-approved option through a trusted platform built to help members access treatment with clinical support and ongoing guidance.”

Weight Watchers Med+ enables access, if appropriate, to medications like Foundayo with an integrated support model designed to help members navigate treatment in real life. Among Med+ members prescribed a GLP-1, those who regularly engaged with the GLP-1 Success Program for 12 months lost 29.1% more body weight, on average, than those who did not engage in behavioral support.

“At Lilly, we are committed to expanding access to innovative treatments that meet the diverse needs of people living with obesity,” said Laura Steele, Group Vice President of U.S. Cardiometabolic Health at Lilly. “Expanding choice means more people can find a treatment pathway that meets patients where they are in their journey.”

“As more and more people are seeking GLP-1 medications, it is more critical than ever for comprehensive care models to support lasting outcomes,” said Mike Mason, a member of Weight Watchers’ Board of Directors and former President of Eli Lilly’s Diabetes and Obesity business. “Weight Watchers stands at the forefront of this evolution with its clinical credibility, behavior change expertise, and community support.”

ABOUT WEIGHT WATCHERS
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]

April 23, 2026 16:01 ET  | Source: WW International Inc.

NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“Weight Watchers” or the “Company”) will release its results for the first quarter 2026 ended March 31, 2026, before market open on Thursday, May 7, 2026.

Weight Watchers will host a conference call to discuss results at 8:30 a.m. ET the same day. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management's current expectations and beliefs, as well as a number of assumptions concerning future events. These statements are subject to risks, uncertainties, assumptions and other important factors. Readers are cautioned not to put undue reliance on such forward-looking statements because actual results may vary materially from those expressed or implied. The reports filed by the Company pursuant to United States securities laws contain discussions of these risks and uncertainties. The Company assumes no obligation to, and expressly disclaims any obligation to, update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers are advised to review the Company's filings with the United States Securities and Exchange Commission (which are available on the SEC's EDGAR database at www.sec.gov and via the Company's website at corporate.ww.com).

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]

On April 30, 2026, Eli Lilly and Co LLY released its 8-K filing detailing first-quarter 2026 results. Revenue rose 56% year over year to $19.8 billion as strong volume growth, led by Mounjaro and Zepbound, more than offset lower realized prices. Reported EPS increased 170% to $8.26 and non-GAAP EPS increased 156% to $8.55. Revenue of $19.80 billion exceeded the estimated revenue of $17.62 billion. Reported EPS of $8.26 was higher than the estimated EPS of $7.02. Non-GAAP EPS of $8.55 was higher than the estimated EPS of $7.02.

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.

Q1 performance and what drove the results Worldwide revenue grew to $19.8 billion, up 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decrease from lower realized prices. Reported net income was $7.4 billion and reported EPS was $8.26, both buoyed by significantly lower acquired IPR&D charges versus the prior year. Non-GAAP net income was $7.7 billion and non-GAAP EPS was $8.55.

Key Products revenue reached $13.4 billion, with growth led by Mounjaro and Zepbound. The company noted that Key Products revenue in Immunology, Oncology, and Neuroscience grew 160% compared to Q1 2025, illustrating broad-based adoption beyond cardiometabolic therapies.

Product and geographic trends Mounjaro revenue increased 125% to $8.7 billion. U.S. sales were $4.2 billion, reflecting strong demand and a favorable one-time rebate and discount adjustment, partially offset by lower realized prices. Revenue outside the U.S. rose to $4.4 billion from $1.2 billion, driven by volume, with lower realized prices reflecting Mounjaro’s addition to China’s NRDL.

U.S. Zepbound revenue was $4.1 billion, up 79%, driven by demand and partially offset by lower realized prices following previously announced cash pay reductions. Outside the U.S., total company revenue climbed 81% to $7.7 billion on 95% volume growth, with price headwinds tied to reimbursement dynamics. Jardiance outside the U.S. included $250 million of one-time collaboration benefits in Q1 2026 compared to $370 million in Q1 2025, a factor to consider in year-over-year comparisons.

2026 is off to a strong start, we delivered 56% revenue growth in the first quarter and raised our full-year revenue guidance by $2 billion," said David A. Ricks, Lilly chair and CEO. “A key milestone was the U.S. FDA approval of Foundayo—the only approved GLP-1 pill that can be taken any time of day, without food and water restrictions. Foundayo will meaningfully expand the number of people who can benefit from GLP-1s. We also delivered pipeline progress across all four therapeutic areas and continued investing in Lilly's future growth through four acquisitions.”Profitability, expenses, and taxes Reported gross margin increased 54% to $16.2 billion, or 81.9% of revenue, down 0.6 percentage points due to lower realized prices. On a non-GAAP basis, gross margin rose 54% to $16.4 billion, or 82.6% of revenue, down 0.9 percentage points.

R&D expense rose 28% to $3.5 billion (18% of revenue) as the company continued investing across early- and late-stage programs. Marketing, selling, and administrative expense increased 19% to $2.9 billion to support ongoing and planned launches. Acquired IPR&D charges were $584 million in Q1 2026 versus $1.6 billion in Q1 2025, reducing the earnings drag this quarter. Asset impairment, restructuring and other special charges were $279 million, primarily related to litigation matters. The effective tax rate declined to 16.4% from 20.2%, reflecting the unfavorable non-deductible IPR&D item in the prior year and net discrete tax benefits. Reported EPS included $0.52 of acquired IPR&D charges compared to $1.72 in Q1 2025.

Eli Lilly and Co — Q1 2026 Snapshot ($ in millions, except per-share data) Revenue $19,799 +56% YoY Analyst estimated revenue $17,615.44 Actual above estimate Net income (reported) $7,396 +168% YoY EPS (reported) $8.26 +170% YoY Analyst estimated EPS $7.02 Actual above estimate Net income (non-GAAP) $7,663 +155% YoY EPS (non-GAAP) $8.55 +156% YoY Gross margin (reported) $16,200 (81.9%) -0.6 pts YoY Gross margin (non-GAAP) $16,400 (82.6%) -0.9 pts YoY R&D expense $3,500 18% of revenue Marketing, selling & admin. $2,900 — Acquired IPR&D charges $584 $1.72/share in Q1’25 vs $0.52/share in Q1’26 Asset impairment/restructuring/other $279 Primarily litigation Effective tax rate (reported) 16.4% 20.2% in Q1’25 Revenue — U.S. $12,100 +43% YoY Revenue — outside U.S. $7,700 +81% YoY Mounjaro revenue (WW) $8,700 +125% YoY Zepbound revenue (U.S.) $4,100 +79% YoY Key Products revenue $13,400 —Guidance, regulatory, and strategic updates Eli Lilly and Co LLY increased 2026 full-year revenue guidance to $82.0 billion to $85.0 billion and non-GAAP EPS guidance to $35.50 to $37.00. Regulatory progress included U.S. FDA approval of Foundayo (orforglipron) for adults with obesity, or overweight with weight-related medical problems. Pipeline updates highlighted positive Phase 3 data across obesity, diabetes, oncology, and immunology programs, including Foundayo in type 2 diabetes and obesity or overweight at increased cardiovascular risk; Jaypirca combinations in relapsed or refractory CLL/SLL; Taltz with Zepbound in psoriasis and obesity or overweight; and retatrutide in type 2 diabetes. Business development activity included agreements to acquire Orna Therapeutics, Centessa Pharmaceuticals plc., Kelonia Therapeutics, and Ajax Therapeutics.

Why the quarter matters and key challenges The quarter confirms accelerating demand for GLP-1–based therapies as a central growth engine. Sustained volume gains in Mounjaro and Zepbound are particularly important in the context of price headwinds, where expanding patient access and reimbursement can pressure realized prices but enlarge the addressable market. The favorable one-time rebate and discount adjustments also aided results, a dynamic that may not repeat each quarter.

Challenges remain. Lower realized prices in both the U.S. and international markets can dampen margin expansion even amid strong volume. The addition of Mounjaro to China’s NRDL underscores significant pricing trade-offs to drive access. Litigation-related charges and elevated commercial investment accompany rapid launches. The reliance on a concentrated set of high-growth products elevates execution and competitive risks typical for large drug manufacturers; continued pipeline diversification and integration of acquisitions are thus strategically important for durability.

Key financial context for investors Gross margin remains high despite pricing pressure, a valuable attribute in branded pharmaceuticals. R&D at 18% of revenue illustrates ongoing reinvestment to support future assets across cardiometabolic, oncology, neuroscience, and immunology. The lower tax rate versus last year aided net income, while reduced IPR&D charges lessened EPS headwinds. These metrics help frame earnings power and cash generation potential as Lilly scales launches and absorbs portfolio investments.

GuruFocus Valuation Check Based on GuruFocus’ proprietary metrics, Eli Lilly and Co LLY appears undervalued relative to GF Value. The GF Value is $1,302.77 versus a current price of $851.21, implying the shares are 34.7% undervalued on this framework.

The overall GF Score is 94/100, which is considered strong. Profitability Rank is 10/10 and Growth Rank is 10/10, a combination that often supports premium multiples in the drug manufacturing industry. Financial Strength is 6/10, which indicates a solid but not exceptional balance sheet profile for a large-cap innovator. Predictability is 3.5 stars, suggesting a reasonably consistent operating record, and the Moat Score of 8/10 points to durable competitive advantages rooted in innovation, scale, and portfolio breadth.

Insider Activity shows no insider transactions in the last three months, which is a neutral signal. For a deeper dive, visit the Eli Lilly and Co stock page on GuruFocus.

Explore the complete 8-K earnings release (here) from Eli Lilly and Co for further details.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Total End of Period Subscribers of 2.7 million; End of Period Clinical Subscribers of 197 thousand, up 46% year-over-year

Revenue of $168 million; Clinical Subscription Revenue of $39 million, up 32% year-over-year

Reaffirms Full Year 2026 Financial Guidance

Announces Fully Subscribed Debt Prepayment Solicitation as Part of Actions Expected to Reduce Debt by $42 Million

NEW YORK, May 07, 2026 (GLOBE NEWSWIRE) -- WW International, Inc. (Nasdaq: WW) (“Weight Watchers” or the “Company”), the global leader in science-backed weight management, today announced its results for the first quarter of fiscal 2026 ended March 31, 20261 in this Earnings Press Release and a Shareholder Letter issued today and posted on the Company’s Corporate Website.

“We remain confident in our strategy to build the industry-leading weight health platform. Our focus is on executing high-impact initiatives that drive Clinical growth and stabilize our Behavioral business,” said Jon Volkmann, Chief Operations Officer and member of the Company’s Interim Office of the Chief Executive. “We made encouraging progress in Q1, with End of Period Clinical Subscribers growing 51% sequentially, and Core+, our higher value Behavioral tier that includes expert support and community experiences, returning to year-over-year growth.”

“We are pleased with our Q1 results. Adjusted Gross Margin2 remains near record highs as we continue to drive operational efficiencies across our portfolio of businesses,” said Felicia DellaFortuna, Chief Financial Officer and member of the Company’s Interim Office of the Chief Executive. “We are reaffirming our 2026 Revenue and Adjusted EBITDA2 guidance and expect Adjusted EBITDA2 and cash generation to increase in the remaining quarters of 2026. Our strengthened capital structure, including the recently announced debt prepayment actions, position us to execute on our transformation while maintaining financial discipline.”

Q1 Business Updates

Q1 2026 Clinical Subscription Revenue grew 32% year-over-year and End of Period Clinical Subscribers grew 46% year-over-year, despite lapping significant prior year growth in Q1 2025 from the Company’s former compounded semaglutide offering.Core+ represented 537 thousand of End of Period Subscribers at the end of Q1 2026, which increased 6% from 505 thousand End of Period Subscribers at the end of Q1 2025.Q1 Monthly Subscription Revenue Per Average Subscriber (ARPU) increased 13% year-over-year, reflecting a continued mix shift towards the Company’s higher ARPU Med+ and Core+ membership tiers. This mix shift partially offset secular headwinds in the Company’s Core membership tier that drove a 10% decrease in Revenue year-over-year.Q1 Gross Margin was 70.5%. Q1 Adjusted Gross Margin2 was 73.6%, which remained near record highs, despite an accelerating mix shift towards Clinical, as margin profiles improved through structural actions and operational efficiencies.Q1 Net Loss was $52.0 million, which reflects higher depreciation and amortization related to Fresh Start Accounting1. Q1 Adjusted EBITDA2 was a loss of $1.8 million reflecting marketing investment in peak season. Balance Sheet and Liquidity Updates

Cash and Cash Equivalents balance as of March 31, 2026 was $121 million.In Q2 2026, the Company expects to pay $37 million in cash to prepay and reduce the principal amount of its outstanding term loan. The prepayment will be comprised of the following two components: In June 2026, $27 million in aggregate principal amount of prepayment from the annual cash sweep; andIn May 2026, $10 million as part of the previously announced voluntary solicitation, which was fully subscribed at 68.5% of par. The Company expects these actions to reduce the aggregate principal amount of its outstanding term loan by $42 million, utilizing $37 million of cash, and to reduce its annualized interest expense by approximately $4 million3.

Fiscal 2026 Guidance

The Company reaffirms previously provided full year fiscal 2026 guidance.

Revenue guidance of $620 million to $635 million.Adjusted EBITDA2 guidance of $105 million to $115 million. First Quarter 2026 Conference Call and Webcast

The Company has scheduled a conference call today at 8:30 a.m. ET to discuss results. The webcast of the conference call will be available on the Company’s corporate website, corporate.ww.com, under Events and Presentations. A replay of the webcast will be available on this site for at least 90 days.

1Fresh Start Accounting and Predecessor and Successor Periods

In connection with the Company’s emergence from its financial reorganization process on June 24, 2025, the Company applied fresh start accounting which resulted in Successor and Predecessor financial statement presentation. References to “Successor” relate to the Company’s operations for the three months ended March 31, 2026 and the period from June 25, 2025 through December 31, 2025. References to “Predecessor” relate to the Company’s operations for the three months ended March 29, 2025. Accordingly, the consolidated financial statements after June 24, 2025 are not comparable with the consolidated financial statements as of or prior to that date.

2Statement regarding Non-GAAP Financial Measures

To supplement the Company’s consolidated results presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company has disclosed non-GAAP financial measures of operating results that exclude or adjust certain items. The Company presents in this release non-GAAP financial measures, including earnings before interest, taxes, depreciation and amortization expenses and share-based compensation expense (“EBITDA”); and for each period presented, EBITDA adjusted, as applicable, for (a) goodwill and other intangible assets impairments, (b) reorganization items, net related to the Company’s emergence from its Chapter 11 financial reorganization, (c) transaction costs related to strategic alternatives and the Company’s Chapter 11 financial reorganization, (d) net restructuring charges associated with the previously disclosed 2025, 2024, and 2023 restructuring plans, (e) non-CEO executive separation expenses and (f) other items such as the impact of foreign exchange gains and losses as indicated in the reconciliations below that management believes are not indicative of ongoing operations (“Adjusted EBITDA”). The Company also presents gross profit, gross margin, marketing expenses, selling, general and administrative expenses, and product development expenses on a non-GAAP basis that adjusts for similar items, as further indicated in the reconciliations below.

As exchange rates are an important factor in understanding period-to-period comparisons, the Company believes in certain cases the presentation of results on a constant currency basis in addition to reported results helps improve investors’ ability to understand the Company’s operating results and evaluate the Company’s performance in comparison to prior periods. Constant currency information compares results between periods as if exchange rates had remained constant period-over-period. The Company uses results on a constant currency basis as one measure to evaluate the Company’s performance. In this press release, the Company calculates constant currency by calculating current-year results using prior-year foreign currency exchange rates. The Company generally refers to such amounts calculated on a constant currency basis as excluding or adjusting for the impact of foreign currency or being on a constant currency basis. These results should be considered in addition to, not as a substitute for, results reported in accordance with GAAP and are not meant to be considered in isolation. Results on a constant currency basis, as the Company presents them, may not be comparable to similarly titled measures used by other companies and are not measures of performance presented in accordance with GAAP.

Management believes these non-GAAP financial measures provide useful supplemental information to investors regarding the performance of the Company’s business and are useful for period-over-period comparisons of the performance of the Company’s business. While the Company believes that these non-GAAP financial measures are useful in evaluating the Company’s business, this information should be considered as supplemental in nature and is not meant to be considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the same as similarly titled measures reported by other companies. See “Reconciliation of Non-GAAP Financial Measures” in this release and reconciliations, if any, included elsewhere in this release for a reconciliation of the non-GAAP financial measures to the most directly comparable GAAP measures.

A reconciliation of the forward-looking full year Adjusted EBITDA outlook to net income cannot be provided without unreasonable effort because of the inherent difficulty of accurately forecasting the occurrence and financial impact of the various adjusting items necessary for such reconciliation that have not yet occurred, are out of the Company’s control, or cannot be reasonably predicted. For the same reasons, the Company is unable to assess the probable significance of the unavailable information, which could have a material impact on its future GAAP financial results.

3The interest rate in effect for the term loan as of March 31, 2026 was 10.51%.

Definitions

“Behavioral” business refers to providing subscriptions to the Company’s digital product offerings with the option to add on unlimited access to the Company’s workshops.

“Clinical” business refers to providing subscriptions to the Company’s clinical product offerings provided by Weight Watchers Clinic combined with the Company’s digital subscription product offerings and unlimited access to the Company’s workshops.

“Revenue” - “Subscription Revenue” consists of the aggregate of: (a) “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings. In addition, “Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. “Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.

“Incoming Subscribers” - “Subscribers” refer to Behavioral subscribers and Clinical subscribers who participate in recurring bill programs in Company-owned operations. The “Incoming Subscribers” metric reports Subscribers in Company-owned operations at a given period start. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“End of Period Subscribers” - The “End of Period Subscribers” metric reports Subscribers in Company-owned operations at a given period end. Recruitment and retention are key drivers for this metric. Management utilizes this metric to monitor changes in the subscriber base which directly impacts the Company’s revenue growth and trends.

“Monthly Subscription Revenue Per Average Subscriber” (“ARPU”) - The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company’s offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for both quarterly and year-to-date periods for each respective business are calculated as Subscription Revenue divided by the number of months in the respective quarterly or year-to-date period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. The “Average Subscriber” for year-to-date periods for each respective business is the average of its Incoming Subscribers at the beginning of the fiscal year and its End of Period Subscribers for each quarter end within the respective year-to-date period. Management utilizes this metric to consider revenue growth and trends on a per subscriber basis.

About Weight Watchers
Weight Watchers is the global leader in science-backed weight management, offering an integrated support system built for the GLP-1 era that combines scientific expertise, medication, cutting-edge technology, and human connection. With more than 60 years of experience, Weight Watchers is the most studied commercial weight management program in the world, delivered through its No. 1 U.S. doctor-recommended weight-loss program. Its holistic, personalized approach also includes U.S.-based clinical interventions and access to GLP-1 medications when clinically appropriate, and a global network of coaches and community support. Since 1963, the company has led with science to deliver its members the personalized support they need to reach and sustain their goals. Members can access these solutions directly, or through Weight Watchers for Business’ full-spectrum platform for employers, health plans, and payers. In a landscape crowded with contradictory advice, isolating apps, and one-size-fits-all solutions, Weight Watchers offers a proven path forward that is rooted in research, grounded in empathy and designed to help every member feel better in their body and live a longer, healthier life. For more information, visit weightwatchers.com.

This news release includes “forward-looking statements,” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, in particular, any statements about the Company’s plans, strategies, objectives, initiatives, and prospects. The Company generally uses the words “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “plan,” “intend,” “aim” and similar expressions in this news release to identify forward-looking statements. The Company bases these forward-looking statements on its current views with respect to future events and financial performance. Actual results could differ materially from those projected in the forward-looking statements. These forward-looking statements are subject to risks, uncertainties and assumptions, including, among other things: the Company's recent emergence from bankruptcy, which could adversely affect its business and relationships and subjects us to risks and uncertainties; competition from other weight management and health and wellness industry participants or the development of more effective or more favorably perceived weight management methods; the Company's failure to continue to retain and grow its subscriber base; the Company's ability to be a leader in the rapidly evolving and increasingly competitive clinical weight management and weight loss market; the Company's ability to continue to develop new, innovative services and products and enhance its existing services and products or the failure of its services, products or brands to continue to appeal to the market, or its ability to successfully expand into new channels of distribution or respond to consumer trends or sentiment; the Company's ability to successfully implement strategic initiatives; the effectiveness and efficiency of its advertising and marketing programs, including the strength of its social media presence; the impact on the Company's reputation of actions taken by its franchisees, licensees, suppliers, affiliated provider entities, PCs’ healthcare professionals, and other partners; the recognition of asset impairment charges; the loss of key personnel, strategic partners or consultants or failure to effectively manage and motivate the Company's workforce; the Company’s chief executive officer transition, and its ability to appoint a new chief executive officer with the required level of experience and expertise in a timely manner; the Company's ability to successfully make acquisitions or enter into collaborations or joint ventures, including its ability to successfully integrate, operate or realize the anticipated benefits of such businesses; uncertainties related to a downturn in general economic conditions or consumer confidence, including as a result of the existing inflationary environment, changes in tariffs and escalating trade tensions, rising interest rates, the potential impact of political and social unrest and increased volatility in the credit and capital markets; the seasonal nature of the Company's business; the Company's failure to maintain effective internal control over financial reporting; the impact of events that impede accessing resources or discourage or impede people from gathering with others; the early termination by us of leases; the inability to renew certain of the Company's licenses, or the inability to do so on terms that are favorable to us; the dependence of the Company's payments system on third-party service providers; the impact of the Company's exposure to variable rate indebtedness; the ability to generate sufficient cash to service the Company's debt and satisfy its other liquidity requirements; uncertainties regarding the satisfactory operation of the Company's technology or systems; the impact of data security breaches and other malicious acts or privacy concerns, including the costs of compliance with evolving privacy laws and regulations; the Company's ability to successfully integrate and use artificial intelligence in its business; the Company's ability to enforce its intellectual property rights both domestically and internationally, as well as the impact of its involvement in any claims related to intellectual property rights; the impact of existing and future laws and regulations; risks related to the Company's exposure to extensive and complex healthcare laws and regulations; the outcomes of litigation or regulatory actions; risks and uncertainties associated with the Company's international operations, including regulatory, economic, political, social, intellectual property, and foreign currency risks, which risks may be exacerbated as a result of war and terrorism; the Company's ability to engage in share repurchases and pay cash dividends in the foreseeable future; risks related to the actions of activist shareholders and anti-takeover provisions in the Company's articles of incorporation and bylaws; risks related to the actions of the Company's shareholders and the exclusive forum provisions in its articles of incorporation; the possibility that the Company could fail to maintain the listing of the Company's common stock on Nasdaq; and other risks and uncertainties, including those included in this press release and those detailed from time to time in the Company’s periodic reports filed with the Securities and Exchange Commission (the “SEC”) (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com). You should not put undue reliance on any forward-looking statements. You should understand that many important factors, including those discussed herein, could cause the Company’s results to differ materially from those expressed or suggested in any forward-looking statement. Except as required by law, the Company does not undertake any obligation to update or revise these forward-looking statements to reflect new information or events or circumstances that occur after the date of this news release or to reflect the occurrence of unanticipated events or otherwise. Readers are advised to review the Company’s filings with the SEC (which are available on the SEC’s EDGAR database at www.sec.gov and via the Company’s website at corporate.ww.com).

For investor inquiries, please contact:
John Mills or Anna Kate Heller
[email protected]

For media inquiries, please contact:
Lizzy Levitan
[email protected]

WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED BALANCE SHEETS(IN THOUSANDS)UNAUDITED            Successor  March 31, December 31,   2026   2025 ASSETS    CURRENT ASSETS    Cash and cash equivalents $120,870  $160,279 Restricted cash  5,797   6,298 Receivables (net of allowances: March 31, 2026 - $1,935 and December 31, 2025 - $1,651)  16,856   16,378 Prepaid income taxes  3,325   8,097 Prepaid marketing and advertising  5,150   9,275 Prepaid expenses and other current assets  16,347   13,277 TOTAL CURRENT ASSETS  168,345   213,604 Property and equipment, net  7,485   8,115 Operating lease assets  2,549   2,933 Goodwill  200,000   200,135 Other intangible assets, net  471,528   490,664 Deferred income taxes  16,254   16,482 Other noncurrent assets  14,910   14,825 TOTAL ASSETS $881,071  $946,758 LIABILITIES AND EQUITY    CURRENT LIABILITIES    Portion of long-term debt due within one year, net $26,808  $— Portion of operating lease liabilities due within one year  1,183   1,260 Accounts payable  17,077   9,212 Salaries and wages payable  20,364   34,375 Accrued marketing and advertising  15,875   22,985 Accrued interest  1,086   1,084 Other accrued liabilities  21,641   23,049 Income taxes payable  10,311   6,006 Deferred revenue  26,749   28,565 TOTAL CURRENT LIABILITIES  141,094   126,536 Long-term debt, net  438,632   465,466 Long-term operating lease liabilities  1,571   1,893 Deferred income taxes  33,705   34,021 Other noncurrent liabilities  498   771 TOTAL LIABILITIES  615,500   628,687 EQUITY    Successor common stock, $0 par value; 1,000,000 shares authorized; 9.996 shares issued at March 31, 2026 and 9,992 shares issued at December 31, 2025  379,306   378,777 Accumulated deficit  (114,095)  (62,095)Accumulated other comprehensive income  360   1,389 TOTAL EQUITY  265,571   318,071 TOTAL LIABILITIES AND TOTAL EQUITY $881,071  $946,758  WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF OPERATIONS(IN THOUSANDS, EXCEPT PER SHARE AMOUNTS)UNAUDITED              Successor  Predecessor  Three Months Ended  Three Months Ended  March 31, 2026  March 29, 2025Subscription revenue, net(1) $167,357   $185,180 Other revenue, net(2)  904    1,391 Revenue, net  168,261    186,571 Cost of subscription revenue(3)  49,445    53,587 Cost of other revenue  144    108 Cost of revenue  49,589    53,695 Gross profit  118,672    132,876 Marketing expenses  92,934    78,778 Product development expenses  8,093    11,121 Selling, general and administrative expenses  48,084    35,629 Franchise rights acquired impairments  —    27,549 Operating loss  (30,439)   (20,201)Interest expense  11,475    27,603 Other (income) expense, net  (737)   2,206 Loss before income taxes  (41,177)   (50,010)Provision for income taxes  10,823    22,575 Net loss $(52,000)  $(72,585)      Net loss per share     Basic $(5.20)  $(0.91)Diluted $(5.20)  $(0.91)      Weighted average common shares outstanding     Basic  9,996    80,129 Diluted  9,996    80,129             Note: Totals may not sum due to rounding.     (1)“Subscription revenue, net” consists of the aggregate of: (a) net “Behavioral Subscription Revenue”, the fees associated with subscriptions for the Company’s Behavioral offerings; and (b) net “Clinical Subscription Revenue”, the fees associated with subscriptions for the Company’s Clinical offerings.(2)“Other revenue, net” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue.(3)“Cost of subscription revenue” consists of cost of revenue and operating expenses for the Company's Behavioral and Clinical services. WW INTERNATIONAL, INC. AND SUBSIDIARIESCONSOLIDATED STATEMENTS OF CASH FLOWS(IN THOUSANDS)UNAUDITED              Successor  Predecessor  Three Months Ended  Three Months Ended  March 31, 2026  March 29, 2025Operating activities:     Net loss $(52,000)  $(72,585)Adjustments to reconcile net loss to cash (used for) provided by operating activities:     Depreciation and amortization  25,886    6,914 Amortization of deferred financing costs and debt (premium) discount, net  (26)   1,254 Impairment of franchise rights acquired  —    27,549 Impairment of intangible and long-lived assets  3    94 Share-based compensation expense  391    860 Deferred tax benefit  (312)   (2,529)Allowance for doubtful accounts  100    84 Foreign currency exchange rate (gain) loss  (738)   2,238 Changes in cash due to:     Receivables  (688)   761 Prepaid expenses  5,835    5,946 Accounts payable  7,556    19,435 Accrued liabilities  (21,854)   8,785 Deferred revenue  (1,722)   (154)Other long term assets and liabilities, net  (302)   (107)Income taxes  4,324    16,453 Cash (used for) provided by operating activities  (33,547)   14,998 Investing activities:     Capital expenditures  —    (5)Capitalized software and website development expenditures  (5,797)   (3,170)Cash used for investing activities  (5,797)   (3,175)Financing activities:     Borrowings on revolving credit facility  —    171,341 Taxes paid related to net share settlement of equity awards  —    (93)Cash provided by financing activities  —    171,248 Effect of exchange rate changes on cash and cash equivalents and restricted cash  (566)   1,529 Net (decrease) increase in cash and cash equivalents and restricted cash  (39,910)   184,600 Cash and cash equivalents and restricted cash, beginning of period  166,577    56,520 Cash and cash equivalents and restricted cash, end of period $126,667   $241,120        WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                              Variance  Successor Predecessor   2026
  Three Months Ended Three Months Ended2026
 Constant Currency  March 31, 2026 March 29, 2025 vs vs  GAAP Constant Currency GAAP 2025
 2025
           Selected Financial Data         Revenue(1)$168,261 $164,007 $186,571 (9.8%) (12.1%)Behavioral Subscription Revenue(2)$128,524 $124,317 $155,723 (17.5%) (20.2%)Clinical Subscription Revenue(3)$38,833 $38,833 $29,457 31.8% 31.8%Subscription Revenue(4)$167,357 $163,150 $185,180 (9.6%) (11.9%)Other Revenue(5)$904 $858 $1,391 (35.0%) (38.3%)                      Note: Totals may not sum due to rounding.         (1)“Revenue” consists of the aggregate of Subscription Revenue and Other Revenue.(2)“Behavioral Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Behavioral offerings.(3)“Clinical Subscription Revenue” consists of the fees associated with subscriptions for the Company’s Clinical offerings.(4)“Subscription Revenue” is the sum of Behavioral Subscription Revenue and Clinical Subscription Revenue.(5)“Other Revenue” consists of revenue from licensing, franchise fees with respect to commitment plans and royalties, publishing and other revenue. WW INTERNATIONAL, INC. AND SUBSIDIARIESOPERATIONAL STATISTICS(IN THOUSANDS, EXCEPT PERCENTAGES AND MONTHLY SUBSCRIPTION REVENUE PER AVERAGE SUBSCRIBER)UNAUDITED                                 Successor Predecessor      Three Months Ended Three Months Ended      March 31, 2026 March 29, 2025 Variance Variance    (Constant Currency)     (Constant Currency)Incoming Subscribers(1)         Incoming Behavioral Subscribers 2,631 N/A  3,244 (18.9%) N/AIncoming Clinical Subscribers 130 N/A  92 41.9% N/AIncoming Subscribers 2,761 N/A  3,336 (17.2%) N/A           End of Period Subscribers(2)         End of Period Behavioral Subscribers 2,463 N/A  3,299 (25.4%) N/AEnd of Period Clinical Subscribers 197 N/A  135 45.9% N/AEnd of Period Subscribers 2,659 N/A  3,434 (22.6%) N/A           Monthly Subscription Revenue Per Average Subscriber(3)         Monthly Behavioral Subscription Revenue Per Average Subscriber$16.82 $16.27 $15.87 6.0% 2.6%Monthly Clinical Subscription Revenue Per Average Subscriber$79.23 $79.23 $86.70 (8.6%) (8.6%)Monthly Subscription Revenue Per Average Subscriber$20.59 $20.07 $18.24 12.9% 10.0%                      Note: Totals may not sum due to rounding.         (1)The “Incoming Subscribers” metric reports WW subscribers in Company-owned operations at a given period start.(2)The “End of Period Subscribers” metric reports WW subscribers in Company-owned operations at a given period end.(3)The “Monthly Subscription Revenue Per Average Subscriber” metric reports the monthly fees associated with subscriptions for the Company's offerings divided by the Average Subscriber for its businesses. Monthly Subscription Revenue for quarterly periods for each respective business is calculated as Subscription Revenue divided by the number of months in the respective quarterly period. The “Average Subscriber” for quarterly periods for each respective business is the average of its Incoming Subscribers and End of Period Subscribers for the respective quarterly period. WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED                                                        Successor  Predecessor  Three Months Ended  Three Months Ended  March 31, 2026  March 29, 2025        Selling,        Selling,      Product General, and      Product General, and  Gross Marketing Development Administrative Gross Marketing Development Administrative  Profit Expenses Expenses Expenses  Profit Expenses Expenses Expenses                  GAAP$118,672  $92,934  $8,093  $48,084   $132,876  $78,778  $11,121  $35,629 % of Revenue 70.5%  55.2%  4.8%  28.6%   71.2%  42.2%  6.0%  19.1%                  Adjustments:                Transaction Costs(1)$—  $—  $—  $—   $—  $—  $—  $(10,823)Depreciation and Amortization Expenses 5,180   —   —   (20,706)   4,500   —   (61)  (2,354)Restructuring Charges(2) (65)  —   —   (533)   (384)  —   —   (1,356)Share-based Compensation Expense 0   (141)  (109)  (436)   —   —   —   (860)Non-CEO Executive Separation Expenses(3)  —   —   —   (1,563)   —   —   —   — Total Adjustments$5,115  $(141) $(109) $(23,238)  $4,116  $—  $(61) $(15,394)                  Adjusted$123,787  $92,793  $7,984  $24,846   $136,992  $78,778  $11,060  $20,235 % of Revenue 73.6%  55.1%  4.7%  14.8%   73.4%  42.2%  5.9%  10.8%                  Currency Adjustment (3,690)  (959)  —   (301)  N/A N/A N/A N/A                  Constant Currency$114,982  $91,975  $8,093  $47,783   N/A N/A N/A N/A% of Revenue 70.1%  56.1%  4.9%  29.1%  N/A N/A N/A N/A                  Adjusted Constant Currency$120,097  $91,834  $7,984  $24,546   N/A N/A N/A N/A% of Revenue 73.2%  56.0%  4.9%  15.0%  N/A N/A N/A N/A                                    Note: Totals may not sum due to rounding.                (1)Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization.(2)Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.(3)Certain non-recurring expenses in connection with the separation from the Company of a non-Chief Executive Officer executive. WW INTERNATIONAL, INC. AND SUBSIDIARIESRECONCILIATION OF NON-GAAP FINANCIAL MEASURES(IN THOUSANDS, EXCEPT PERCENTAGES)UNAUDITED              Successor  Predecessor  Three Months Ended  Three Months Ended  March 31, 2026  March 29, 2025      Net Loss $(52,000)  $(72,585)Net Loss Margin  (30.9%)   (38.9%)      Interest  11,475    27,603 Taxes  10,823    22,575 Depreciation and Amortization Expenses  25,886    6,914 Share-based Compensation Expense  686    860 EBITDA $(3,130)  $(14,633)EBITDA Margin  (1.9%)   (7.8%)      Franchise Rights Acquired Impairments(1)  —    27,549 Transaction Costs(2)  —    10,823 Restructuring Charges(3)  468    972 Non-CEO Executive Separation Expenses(4)  1,563    — Other(5)  (737)   2,206 Adjusted EBITDA $(1,836)  $26,917 Adjusted EBITDA Margin  (1.1%)   14.4%            Note: Totals may not sum due to rounding.     (1)The Company's franchise rights acquired impairment charge related to its United States unit of account.(2)Certain non-recurring transaction costs related to strategic alternatives and the Company's Chapter 11 financial reorganization.(3)Restructuring charges consist of expenses associated with the reduction in headcount as a result of certain strategic re-alignments. Restructuring charges include the previously disclosed 2025 restructuring plan, the previously disclosed 2024 restructuring plan and the previously disclosed 2023 restructuring plan.(4)Certain non-recurring expenses in connection with the separation from the Company of a non-Chief Executive Officer executive.(5)Primarily consists of the impact of foreign exchange gains and losses.

2 hours ago

MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in StockMarketBeat

MSA Safety Incorporporated (NYSE:MSA - Get Free Report) CFO Julie Beck bought 448 shares of the stock in a transaction dated Thursday, June 11th. The stock was acquired at an average price of $158.69 per share, with a total value of $71,093.12. Following the completion of the purchase, the chief financial officer owned 3,825 shares of the company's stock, valued at $606,989.25. This represents a 13.27% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

NYSE:MSA

Read MSA Safety Incorporporated (NYSE:MSA) CFO Acquires $71,093.12 in Stock

2 hours ago

Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of StockMarketBeat

NBT Bancorp Inc. (NASDAQ:NBTB - Get Free Report) Director Heidi Hoeller sold 2,100 shares of the business's stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $48.03, for a total transaction of $100,863.00. Following the transaction, the director owned 11,560 shares of the company's stock, valued at approximately $555,226.80. This represents a 15.37% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

NASDAQ:NBTB

Read Insider Selling: NBT Bancorp (NASDAQ:NBTB) Director Sells 2,100 Shares of Stock

2 hours ago

Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) StockMarketBeat

IGM Financial Inc. (TSE:IGM - Get Free Report) Director Douglas Milne sold 1,600 shares of the business's stock in a transaction that occurred on Tuesday, June 9th. The stock was sold at an average price of C$80.61, for a total value of C$128,976.00. Following the sale, the director directly owned 800 shares in the company, valued at C$64,488. The trade was a 66.67% decrease in their ownership of the stock.

TSE:IGM

Read Douglas Milne Sells 1,600 Shares of IGM Financial (TSE:IGM) Stock

2 hours ago

GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 SharesMarketBeat

GlobalFoundries Inc. (NASDAQ:GFS - Get Free Report) insider Michael James Hogan sold 2,800 shares of GlobalFoundries stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $75.17, for a total value of $210,476.00. Following the transaction, the insider owned 6,695 shares in the company, valued at $503,263.15. This trade represents a 29.49% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

NASDAQ:GFS

Read GlobalFoundries (NASDAQ:GFS) Insider Michael James Hogan Sells 2,800 Shares

Sort By

Time Frame

Alert Type

Keywords

Page 1 of 325

-

NEW YORK--(BUSINESS WIRE)--Galloway Capital Partners, LLC (“Galloway”), together with its affiliates, today announced that it has accumulated an ownership stake of approximately 8.42% in WW International, Inc. (“WW” or the “Company”).

Galloway believes WW is materially undervalued despite owning one of the world’s most recognized wellness brands and operating in the rapidly growing markets of weight management, metabolic health, GLP-1 support, and longevity.

Following its recent restructuring, WW reduced debt from approximately $1.4 billion to roughly $460 million while maintaining more than $220 million of cash on its balance sheet. Despite this improved capital structure, the Company’s market capitalization has fallen to less than $100 million.

“We believe the market is dramatically undervaluing WW’s brand, clinical business, member ecosystem, and long-term strategic potential,” said Bruce Galloway, Chief Investment Officer of Galloway Capital Partners.

Galloway noted that WW’s clinical business is growing more than 50% annually and believes the Company’s approximately 2.8 million members, combined with decades of proprietary consumer data, represent a highly valuable strategic asset in an increasingly personalized healthcare and wellness environment.

At current levels, WW trades at approximately 3.7x EBITDA, a substantial discount to peers in the digital health and wellness sector.

Galloway also stated that the Company has an opportunity to recruit a transformational CEO with expertise in consumer health, digital wellness, and subscription-based healthcare platforms.

“We believe WW is worth a multiple of its current trading value and look forward to engaging constructively with the Board and management team to help unlock shareholder value,” added Galloway.

More News From Galloway Capital Partners, LLC

Back to Newsroom

Unlimited Day PassSM gives eligible U.S. iPad Users — Including Verizon and T-Mobile Customers — Unlimited Data for $3 a Day, With No Contracts or Subscriptions.

Key Takeaways:

AT&T is the first and only major U.S. wireless provider to offer on-demand connectivity for eligible U.S. iPad users, regardless of the customer's carrier.AT&T Unlimited Day Pass includes unlimited data1 for just *$3 a day2 with no contracts, subscriptions or credit checks required.Customer's first day pass is complimentary, courtesy of AT&T (limit one iPad per customer)3., /PRNewswire/ -- What's the News: Today, AT&T launched Unlimited Day Pass, a 24-hour unlimited wireless data1 connection for eligible U.S. iPad users, including non-AT&T customers, for a daily2 *$3 flat rate — with no contracts, subscriptions or credit checks required.

AT&T is the first and only major U.S. wireless provider to give eligible iPad users (with eSIM capabilities) the freedom to buy on-demand connectivity when they need it.

Why it Matters: Many consumers have iPads that are not connected to cellular plans4. We want to give those people — regardless of their wireless provider — the ability to connect their iPads anytime, anywhere with no long-term commitment. This new product is a flexible option that delivers dependable and secure access on demand for Wi-Fi + Cellular iPad users, ideal for travel days, busy workdays or moments when Wi‑Fi isn't available.

How it Works:

The first day pass is complimentary, courtesy of AT&T (limit one iPad per customer)3, and available for a flat, daily2 rate via credit or debit card after that.Activate Wi-Fi +Cellular iPad model directly from your device settings — no app or Wi-Fi connection required5. Open the Settings app, tap Cellular Data, add AT&T Unlimited Day Pass.24-hour data activation begins shortly after purchase.Quotable: "Our goal with any product is to make it simple for people to connect wherever they are, across the devices they use most," said Josh Goodell, vice president, Consumer Product Management for AT&T. "Unlimited Day Pass delivers on-demand connectivity for Wi-Fi + Cellular iPad models on the nation's largest wireless network6, whether someone is an AT&T customer or not, for a flat daily fee. There is no long-term commitment — just the connectivity you need, when and where you need it."

More Details: AT&T Unlimited Day Pass is the latest example of how we are simplifying the connectivity experience by giving people more flexibility and value without locking them into monthly contracts or subscriptions. Unlimited Day Pass will continue to evolve to reach more customers on other 5G enabled wireless devices while delivering an even simpler, more seamless, on-demand connectivity experience in the near future.

For more information on AT&T Unlimited Day Pass, please visit https://www.att.com/wirelessdaypass

FAQ

Q: What iPads are eligible for Unlimited Day Pass?
All iPads must be cellular based with eSIM capabilities. The following iPads are currently eligible:

iPad Pro 11 (A2013)iPad Air 13-inch (M3) Ch A3271iPad Pro 11in (3rd gen) A2301 (NA)iPad (A16) A3355iPad Pro 12.9in (6th gen) - A2764 (WW)iPad Pro 13 A2926 (2024)iPad (A16) Ch A3356iPad Air 11 A2903 (2024)iPad 9th Gen A2603 (NA)iPad (10th gen) - A2757 (WW)iPad Pro 12.9in (5th gen) A2379 (NA)iPad Mini 5G A2568 (NA-RoW)iPad Pro 11 A2837 (2024)iPad Pro 11in (4th gen) - A2435 (WW)iPad Air 13 A2899 (2024)iPad Pro 12-in. (4th generation) A2069iPad 7 Gen A2200A2126 7.9 iPad mini (5th Gen)A2153 10.5 iPad Air (3rd Gen)iPad Air 11-inch (M3) A3267iPad Air (A2589) ROW 2022iPad Air 13-inch (M3) A3269iPad Air 11-inch (M3) Ch A3270iPad Mini (2024)iPad Pro 11-in. (2nd generation) A2068iPad 8th gen A2428iPad Air (2020) A2324iPad Pro 12.9 (A2014)iPad Pro A1652Q: Does Unlimited Day Pass work for iPads only? What about other tablets?
At this moment, iPads are only eligible for Unlimited Day Pass. In the near future, other 5G-enabled devices like Android tablets, smartwatches, laptops, drones, etc. are planned to be eligible for Unlimited Day Pass.

Q: Do I have to sign up again every time I want a day pass? Can I buy multiple passes at a time?
At this moment, we are only offering 24-hour passes. In the near future, we plan to expand the Unlimited Day Pass experience to include multi-day options such as weekend and week-long passes.

Q: Do I need to be an existing AT&T mobile customer to purchase the Unlimited Day Pass?
No. Unlimited Day Pass is available to any customer whether you have AT&T mobile service or not. Any customer can purchase their Unlimited Day Pass directly on their eligible iPad with a debit/credit card.

1AT&T may temporarily slow data speeds if the network is busy.
2Req's elig. unlocked, eSIM-capable iPad. 24-hour data activation begins shortly after purchase.
3Subj. to change. First day pass on us with your initial eSIM activation. Limit one per tablet.
4According to 2024 Customer Survey commissioned by AT&T.
5iPad must be cellular enabled for activation.
6Compares ground-based cellular networks. No AT&T on-net coverage in select countries, including Canada.

About AT&T
We help more than 100 million U.S. families, friends and neighbors, plus nearly 2.5 million businesses, connect to greater possibility. From the first phone call 150 years ago to our 5G wireless and multi-gig internet offerings today, we @ATT innovate to improve lives. For more information about AT&T Inc. NYSE:T , please visit us at about.att.com. Investors can learn more at investors.att.com.

© 2026 AT&T Intellectual Property. All rights reserved. AT&T and the Globe logo are registered trademarks of AT&T Intellectual Property.

View original content to download multimedia:https://www.prnewswire.com/news-releases/att-launches-unlimited-day-pass-bringing-connectivity-to-ipad-users-regardless-of-carrier-302795931.html

SOURCE AT&T

Two tankers carrying oil products exited ​the Strait of Hormuz over the past week, while a liquefied natural gas carrier loaded cargo ‌in the United Arab Emirates, shipping data showed - rare movements as traffic through the chokepoint remains limited.

U.S. natural gas futures slid about ​2% on Tuesday as daily flows to liquefied natural gas (LNG) export plants dropped to a four-month low.

Rick Gardner of of RGA Investments says higher defense spending commitments across Europe could support the region's defense stocks, which remain relatively cheaper than U.S. peers. He also sees upside for U.S. LNG exporters, producers and refiners if Europe increasingly looks beyond the Gulf region for energy supplies.

ATHENS, Greece, June 05, 2026 (GLOBE NEWSWIRE) -- Capital Clean Energy Carriers Corp. (the "Company", "CCEC", "we" or "us") (NASDAQ: CCEC), an international owner of ocean-going vessels, today announced the delivery of LNG Carrier ("LNG/C") Archimidis on June 2, 2026, and dual-fuel medium gas carrier Aristogenis on June 4, 2026, as well as new time charter employment secured for three LCO2/LPG carriers and two LNG carriers. Fleet Update — LCO2/LPG Fleet As previously announced, the Company took delivery of its second LCO2/multi-gas carrier, the Amadeus (Hyundai Mipo Dockyard Co. Ltd.

Key Takeaways Cheniere posted $5.9B revenues and exported a record 187 cargoes; adj EBITDA $2.3B, DCF $1.7B.Cheniere estimates ~7M tons/month of LNG supply, about 100 cargoes, still disrupted.Cheniere sees buyers favoring diversity, destination flexibility and reliability in new contracts. Cheniere Energy (LNG - Free Report) is benefiting from a sharper focus on liquefied natural gas (“LNG”) supply security as Middle East disruptions reshape global gas flows. The company delivered a strong first quarter, generating $5.9 billion in revenues, $2.3 billion in consolidated adjusted EBITDA and $1.7 billion in distributable cash flow. It also exported a quarterly record 187 LNG cargoes. This performance came as the closure of the Strait of Hormuz and damage to part of QatarEnergy’s LNG facility tightened an already stretched market.

The disruption has also highlighted the strategic value of U.S. LNG. Cheniere estimates that roughly 7 million tons of LNG supply per month remains disrupted, equal to about 100 cargoes. Since most Qatari volumes typically move into Asia, the supply shock quickly pulled more flexible cargoes toward Asian markets. Cheniere’s U.S.-based LNG portfolio is well-positioned in this environment because its cargoes can be redirected based on market need, helping customers manage sudden supply gaps during volatile periods.

Importantly, the current market stress could support Cheniere’s future contracting efforts. Buyers are likely to place greater emphasis on supply diversity, destination flexibility and producer reliability after seeing how quickly geopolitical events can disrupt LNG availability. Cheniere already serves more than 35 long-term creditworthy counterparties and is working to commercialize additional capacity tied to its expansion plans. Overall, the disruption reinforces the importance of secure U.S. LNG and strengthens Cheniere’s position as a preferred long-term supplier in an increasingly risk-aware global gas market.

The recent disruptions have reinforced the strategic value of LNG assets across the industry. Beyond Cheniere, other companies with significant LNG exposure are also positioned to benefit from stronger demand for secure and flexible gas supplies.

Key LNG Players Benefiting From Supply-Security Focus

Venture Global (VG - Free Report) : Venture Global is scaling quickly as a U.S. LNG supplier, with 68 million tons per annum (“MTPA”) of capacity operating or under construction and a targeted total of about 100 MTPA across Calcasieu Pass, Plaquemines, CP2 and planned bolt-on expansions. Venture Global exported a record 130 cargoes in first-quarter 2026 and had 84% of the expected 2026 cargoes contracted by May 8. Venture Global’s long and medium-term contracts support clearer cash flows while leaving room for market flexibility.

Chevron (CVX - Free Report) : Chevron also remains a major LNG player through its Gorgon and Wheatstone projects in Australia, which give Chevron exposure to steady Asian demand. Gorgon has an LNG capacity of about 15.6 MTPA, while Wheatstone can produce roughly 8.9 MTPA. Chevron operates both projects and holds 47.3% of Gorgon and 64.14% of Wheatstone, giving Chevron a large, reliable LNG platform in a region close to key buyers.

The Zacks Rundown on Cheniere Energy

Shares of LNG have gained around 23% so far this year, slightly underperforming the Oil/Energy sector.

Image Source: Zacks Investment Research

Cheniere Energy currently has an average brokerage recommendation (ABR) of 1.24 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell, etc.) made by 23 brokerage firms.

Image Source: Zacks Investment Research

See how the Zacks Consensus Estimate for Cheniere Energy’s earnings has been revised over the past 60 days.

Image Source: Zacks Investment Research

The stock currently carries a Zacks Rank #3 (Hold).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

June 10, 2026 09:20 ET  | Source: Ignitis grupe

UAB “Ignitis” has secured long-term access to capacity at the Klaipėda liquefied natural gas (LNG) terminal. This will provide access to the global LNG market and support greater flexibility in natural gas supply in the years ahead.

In the long-term capacity allocation procedure conducted by the operator of the Klaipėda LNG terminal, KN Energies, Ignitis booked 4 TWh of annual regasification capacity for the period from 2033 to 2044.

Long-term access to the terminal provides greater flexibility in gas supply planning, enables diversification of supply sources, and strengthens energy resilience in Lithuania and across the Baltic region.

Communications
Valdas Lopeta
+370 621 77993
[email protected] 

U.S. liquefied natural gas company Cheniere Energy's liquefaction midscale trains ​1-6 at the Corpus Christi LNG export plant's ‌Stage 3 expansion in Texas were on track to take in more natural gas on Thursday after shutting down on Wednesday, ​data from financial firm LSEG showed.

Cheniere Energy is rated Buy, with a $300 price target, as recent LNG price normalization creates an attractive entry point. LNG's core assets, Corpus Christi and Sabine Pass, are expanding capacity, supporting long-term EBITDA growth, and improving operating leverage. Guidance was raised post-Q1: adjusted EBITDA $7.25–$7.75B, distributable cash flow $4.25–$5.25B, with potential for further upside if prices hold.

Antero Resources Corporation (AR) Q1 2026 Earnings Call Transcript

Snap SNAP saw its stock decline after releasing its Q1 earnings, despite exceeding earnings per share (EPS) expectations and reporting steady revenue and user growth. Investors are concerned about the slowing advertising momentum, ongoing weaknesses in North American advertising, restructuring costs, and conservative guidance for Q2. However, the quarter showcased significant advancements in revenue diversification, profitability, AI-driven monetization efforts, and subscription growth.

Q1 revenue increased by 12.2% year-over-year to $1.53 billion, aligning with consensus estimates. Adjusted EBITDA more than doubled to $233 million, while the net loss improved to $89 million. Free cash flow reached $286 million, with EBITDA flow-through at 75%, indicating enhanced profitability and cost management. Global Daily Active Users (DAUs) rose 5% year-over-year to 483 million, surpassing expectations, with Monthly Active Users (MAUs) reaching 956 million. Engagement metrics remained robust, with Spotlight posters up nearly 74% in the U.S. and total Spotlight viewing time increasing by 11%. Average Revenue Per User (ARPU) grew by 7% year-over-year to $3.17. However, advertising revenue saw a modest increase of 3% to $1.24 billion, impacted by challenges among large North American advertisers and geopolitical issues in the Middle East. Demand from small and medium-sized businesses (SMBs) and lower-funnel ad products continued to drive growth. Snap made strides in enhancing its AI-powered advertising platform, with Dynamic Product Ads revenue surging over 30%. Nearly 70% of ad spend is now utilizing AI-driven automation tools, while Sponsored Snaps and AI Sponsored Snaps are emerging as important revenue sources. Revenue from "Other Revenue," primarily from Snapchat+ subscriptions, soared 87% year-over-year to $285 million. Management noted strong growth from Memories Storage, Lens+, and AI-powered premium tools as key contributors to long-term ARPU and recurring revenue. Gross margin improved by 300 basis points year-over-year to 57%, with operating expense growth limited to 2%. Snap announced a 16% workforce reduction, expected to cut annual costs by over $500 million in the second half of 2026, although restructuring charges of $95-$130 million will affect Q2 results. Snap ended its partnership with Perplexity AI to focus on developing its internal AI monetization tools and expanded its collaboration with Qualcomm Technologies QCOM to advance future Specs smart glasses development. For Q2, Snap guided revenue between $1.52 billion and $1.55 billion, roughly in line with consensus, and adjusted EBITDA between $175 million and $200 million. Management noted improving trends in North American advertising and stronger upfront commitments, though challenges from the Middle East persist.This quarter demonstrated stronger operational performance than the stock's reaction suggests. Snap is evolving beyond a purely ad-driven platform, with subscriptions, AI monetization, and augmented reality (AR) initiatives becoming increasingly significant growth drivers. The momentum from Snapchat+, improved ad platform efficiency, and expanding margins indicate a structurally stronger business. While weak demand from large advertisers in North America and conservative Q2 guidance remain concerns, the overall trajectory points towards a more diversified, profitable, and cash-generative Snap over time.

This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].